(Reuters) – Novavax (NASDAQ:) Inc mentioned on Thursday it might start industrial manufacturing of a COVID-19 vaccine tailor-made for the Omicron coronavirus variant in January subsequent 12 months, whereas it assessments whether or not or not its present vaccine works towards the variant.
Laboratory (NYSE:) knowledge anticipated within the coming weeks will present whether or not antibodies from people who’ve beforehand acquired Novavax’s COVID-19 shot can neutralize the variant, in keeping with the corporate.
Novavax additionally mentioned it has began creating an Omicron-specific spike protein antigen and can start laboratory assessments of a brand new vaccine to focus on the variant in just a few weeks.
The Omicron coronavirus variant has shaken up markets and prompted world alarm over issues about whether or not it might evade safety offered by broadly used vaccines and delay the general public well being disaster.
Different vaccine makers together with Moderna (NASDAQ:) and Pfizer (NYSE:) have additionally begun engaged on Omicron-tailored COVID-19 pictures.
Novavax’s COVID-19 vaccine acquired its first emergency use approval in Indonesia in early November adopted by the Philippines.
Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or harm because of reliance on the knowledge together with knowledge, quotes, charts and purchase/promote indicators contained inside this web site. Please be absolutely knowledgeable concerning the dangers and prices related to buying and selling the monetary markets, it is likely one of the riskiest funding kinds doable.